The Food Standards Agency (FSA) recently announced that CBD supplements and edibles are to be regarded as Novel Foods. Along with this statement, a deadline of March 31st 2021 was set for CBD sellers to apply for approval. If the guidance goes unheeded, some CBD products may disappear from the UK’s market next year. The FSA’s decision and follow-up direction for CBD producers and sellers is excellent news for Brits enjoying the benefits of CBD oil and edibles.
What is the EU Novel Food Status?
The EU Novel Food status is a way in which countries can ensure the safety of new foods products. This includes newly discovered foods and supplements, traditional foods from other countries, and food developed with new technologies.
Extracts like phytosterols, which are commonly found in cholesterol-lowering spreads, and mycoprotein that makes up Quorn, both began as novel foods. Even chia seeds and baobab extract are considered Novel.
The idea behind achieving Novel Food status is that products without a history of mass consumption can be tested and tried to make sure they are safe. Not only that, any claims about what the new food or compound can do can be verified. This means consumers aren’t misled with unfounded claims and the new food isn’t used to replace any essential food at the detriment of their diet.
What does CBD’s Novel Food Status mean for consumers?
The great thing about the FSA’s decision to classify CBD as a Novel Food is that consumers of CBD products will have assurance that what they are purchasing is what they believe it to be.
Up until now, the burgeoning CBD market has gone largely unregulated. This has allowed some less than honest manufacturers and retailers to make false or inaccurate claims about the concentration of CBD, THC, and other potentially harmful contaminants, in their products
The new regulatory status of over the counter CBD products will ensure that manufacturers will have to successfully pass a stringent vetting process to bring their CBD oil, gummies or other edibles to UK shelves. This ultimately makes for a better and safer marketplace for all, consumers will be able to purchase CBD products with confidence.
FSA guidance on CBD doses
Producers of CBD products have until March 2021 to meet the production standards necessary to apply to Novel Food certification. During this transitional phase, it’s unlikely any CBD brand will have their products seized by trading standards.
In the meantime, the FSA has answered some of the public’s most pressing questions about CBD products. One of which is the correct CBD dosage for those who regularly take it as a supplement. The FSA recommends avoiding CBD products completely if pregnant or breastfeeding and also if taking other medications. For the rest of us, an upper daily limit of 70mg of CBD has been advised. Although this conflicts with the European Industrial Hemp Association’s (EIHA) advice of no more than 160mg of CBD per day, they consider it to be a ‘workable compromise’.
A new level of transparency for the CBD sector
At Future Bright CBD, each product is thoroughly tested, ingredients are organically certified and non-GMO, and every single batch of oil can be easily traced back to the lab reports detailing the CBD profile. We’ll never compromise on these meticulous standards because we are committed to supplying quality assured and safe CBD oil.
This step toward the regulation of the rapidly growing CBD industry is one to celebrate. Increased transparency around CBD products, assurance of quality, and certainty that your CBD product of choice is safe to use is an excellent development for consumers and producers alike.